These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8236141)

  • 1. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen.
    Refino CJ; Paoni NF; Keyt BA; Pater CS; Badillo JM; Wurm FM; Ogez J; Bennett WF
    Thromb Haemost; 1993 Aug; 70(2):313-9. PubMed ID: 8236141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).
    Paoni NF; Keyt BA; Refino CJ; Chow AM; Nguyen HV; Berleau LT; Badillo J; Peña LC; Brady K; Wurm FM
    Thromb Haemost; 1993 Aug; 70(2):307-12. PubMed ID: 8236140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA; Huang TC; Keyt BA; Alevriadou BR
    Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A faster-acting and more potent form of tissue plasminogen activator.
    Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators.
    Eastman D; Wurm FM; van Reis R; Higgins DL
    Biochemistry; 1992 Jan; 31(2):419-22. PubMed ID: 1731899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
    Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
    Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAI-1-resistant t-PA: low doses prevent fibrin deposition in rabbits with increased PAI-1 activity.
    Krishnamurti C; Keyt B; Maglasang P; Alving BM
    Blood; 1996 Jan; 87(1):14-9. PubMed ID: 8547635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of residues 296-299 in the enzymatic activity of tissue-type plasminogen activator.
    Paoni NF; Refino CJ; Brady K; Peña LC; Nguyen HV; Kerr EM; Johnson AC; Wurm FM; van Reis R; Botstein D
    Protein Eng; 1992 Apr; 5(3):259-66. PubMed ID: 1409547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
    J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments.
    Davami F; Sardari S; Majidzadeh-A K; Hemayatkar M; Barkhordari F; Enayati S; Adeli A; Mahboudi F
    BMB Rep; 2011 Jan; 44(1):34-9. PubMed ID: 21266104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
    Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
    Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
    Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
    Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of serine or threonine at position 473 of tissue-type plasminogen activator increases its stability in plasma.
    Alibhai M; Chow AM; Paoni NF
    Thromb Haemost; 1996 Jan; 75(1):107-12. PubMed ID: 8713788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ; Hanson M; FitzGerald GA
    J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
    Collen D; Stassen JM; Larsen G
    Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
    Eggers J; Ossadnik S; Hütten H; Seidel G
    Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.